Opat P, Drbal J, Vyzula R
Research Institute of Clinical and Experimental Oncology, Brno, Czechoslovakia.
Neoplasma. 1989;36(4):489-94.
In the presented clinical study, 10 patients with malignant lymphoproliferative diseases (2 with acute lymphoblastic leukemia, 3 with Hodgkin's disease, and 5 with non-Hodgkin's lymphoma), resistant to standard therapy, were administered alpha-2-recombinant interferon at a dosage of 120 x 10(6) IU as a continuous 48 h i.v. infusion. The second administration was performed after an interval of 1 month. A therapeutic response was seen in 50% of the patients, of them there were two complete remissions (in the two acute lymphoblastic leukemia patients) and 3 partial remissions (in 2 patients with Hodgkin's disease and in 1 patient with low malignant non-Hodgkin's lymphoma). In four patients with high malignant non-Hodgkin's lymphomas the treatment did not evoke any response, and in 1 patient with the same diagnosis progression was noted after the treatment. The toxic effects of the drug were in accord with literature data, and although high doses of alpha-2-recombinant interferon were administered, it was not necessary to interrupt the treatment in any of the patients. Considering the therapeutic effect of this immunomodulator used in the treatment of malignant lymphoproliferative diseases, our results are promising, nevertheless further studies will be required.
在本临床研究中，对10例对标准疗法耐药的恶性淋巴增生性疾病患者（2例急性淋巴细胞白血病、3例霍奇金病、5例非霍奇金淋巴瘤），以120×10⁶IU的剂量静脉连续输注48小时给予α-2重组干扰素。1个月后进行第二次给药。50%的患者出现治疗反应，其中2例完全缓解（2例急性淋巴细胞白血病患者），3例部分缓解（2例霍奇金病患者和1例低恶性非霍奇金淋巴瘤患者）。4例高恶性非霍奇金淋巴瘤患者治疗无反应，1例相同诊断患者治疗后病情进展。药物的毒性作用与文献数据一致，尽管给予了高剂量的α-2重组干扰素，但无需中断任何患者的治疗。考虑到这种免疫调节剂在治疗恶性淋巴增生性疾病中的治疗效果，我们的结果是有前景的，不过仍需要进一步研究。
